ExpreS2ion’s core platform patent allowed in Canada
ExpreS2ion Biotech Holding AB and its affiliate ExpreS2ion Biotechnologies ApS (“ExpreS2ion") announce that the Company’s patent application “Improved Protein Expression System”, that covers the entire ExpreS2 platform, has been allowed in Canada and will be granted with expiry June 12, 2029.
“With the patent allowance in Canada, ExpreS2ion has now successfully obtained patent protection of its ExpreS2 platform in all major markets of interest. Thereby the major initial goal for our ExpreS2 platform patent portfolio, which is fundamental to our business, has been reached," says Dr. Steen Klysner, CEO of ExpreS2ion.
The patent application “Improved Protein Expression System” has been filed in 15 different countries covering the Company’s major markets. The patent has been issued in the United States, South Korea, Japan, Australia, China, India, and validated in several EU countries following approval by the European Patent Office.
Sedermera Fondkommission is appointed as Certified Adviser for ExpreS2ion.
For further information about ExpreS2ion Biotech Holding AB, please contact:
Dr. Steen Klysner, CEO
Telephone: +45 2062 9908
This press release contains information that ExpreS2ion is obligated to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication through the agency of the contact person set out above on May 17, 2017.
ExpreS2ion Biotechnologies ApS is a fully owned Danish subsidiary of ExpreS2ion Biotech Holding AB with company register number 559033-3729. The subsidiary has developed a unique proprietary platform technology, ExpreS2, that can be used for fast and efficient preclinical and clinical development as well as robust production of complex proteins for new vaccines and diagnostics. Since the Company was founded in 2010, it has produced more than 250 proteins and 35 virus-like particles (VLPs) in collaboration with leading research institutions and companies, demonstrating superior efficiency and success rates. In addition, ExpreS2ion develops novel VLP based vaccines through the joint venture AdaptVac ApS which was founded in 2017.